Abstract Details

Title Treatment Patterns of Active and Nonactive Secondary Progressive Multiple Sclerosis Patients in the United States

Topic Multiple Sclerosis

Presentation(s) P1 - Poster Session 1 (9:00 AM-5:00 PM)

Poster/Presentation
Number 308

Objective To determine the treatment patterns of active and nonactive secondary progressive multiple sclerosis (SPMS) patients over time in the United States (US).

Background Published information on treatment patterns as well as the percentage of untreated patients living with active and non-active SPMS is limited.

Design/Methods The Adelphi Disease Specific Programme was used to identify SPMS patients in the US. Treatment patterns from 2013-2017 and 2018-2021 were determined based on the physician-reported annual cross-sectional survey. This was stratified by active SPMS patients, patients with a relapse in the previous year, and nonactive SPMS patients without a relapse in the previous year.

Results A total of 779 SPMS patients (293 active SPMS and 486 nonactive) were evaluated. Mean age was 48.7 years and 70.3% female in active population and 54.2 years and 67.7% were female in nonactive population. Among active SPMS patients, 11.6% did not receive any treatment, 37.2% received injectables, 25% received orals, 25% received infused products, and 1.2% reported other products in 2013-2017; in more recent years (2018-2021), 9.9% were not on any treatment, 23.1% received injectables, 25.6% received orals, 39.7% received infused products, and 1.7% reported other products. Among nonactive SPMS patients, 29.4% did not receive any treatment, 37.6% received injectables, 17.2% received orals, and 14.9% received infused products, and 0.5% reported other products prior to 2018; in the last 4 years, 23.8% were not on any treatment, 14.7% received injectables, 25.3% received orals, 34.3% received infused products, and 1.9% reported other products.

Conclusions This study showed that approximately 10% of active and 25% of nonactive SPMS populations are not on any treatments, even in recent years. Despite available treatments for active SPMS, there continues to be a high unmet need for additional SPMS treatments that are safe and effective; this is especially true in nonactive SPMS, where there are no approved treatments.

Authors/Disclosures
PRESENTER	No disclosure on file
Crystal Watson (Atara Biotherapeutics)	Ms. Watson has received personal compensation for serving as an employee of Atara Biotherapeutics. Ms. Watson has received stock or an ownership interest from Atara Biotherapeutics.
	No disclosure on file
	No disclosure on file
Eddie Jones, BA	Eddie Jones, BA has nothing to disclose.
Sasha Bogdanovich, MD, PhD (AtaraBio)	Dr. Bogdanovich has received personal compensation for serving as an employee of Atara Bio. Dr. Bogdanovich has received stock or an ownership interest from Atara Bio.

��ɫ��

��ɫ��